Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam versus valproic acid monotherapy in children with newly diagnosed epilepsy
NL-OMON39513Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing Levetiracetam monotherapy with Valproic acid monotherapy (2 arms). Primary endpoint: Retention rate after 52 weeks of treatment. Started Feb 2013; status: active, not recruiting.
02
Drugs
levetiracetamvalproic acid
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON39513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39513.